gip y glp 1 Understand GLP-1/GIP Dual Agonist Tirzepatide and Its Effect on Current Weight Loss Therapy GLP-1, GIP and glucagon receptor

Summary: Trulicity should not be combined with other GLP-1 receptor agonists or DPP-4 inhibitors, whilst insulin, sulphonylureas, and warfarin require careful monitoring and possible dose adjustments due to increased hypoglycaemia or altered anticoagulation risk

Comparatively, tirzepatide, the active ingredient in Zepbound and Mounjaro, demonstrated an average weight loss of 22.9% at 176 weeks with the 15 mg dose in the SURMOUNT-1 Phase 3 study in adults with pre-diabetes and obesity or overweight

Yu M, Wang R, Pei Lea, Wang J, Wang L et al (2023) The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials

The right choice depends on provider recommendation, genetic predisposition context, and your clinical profile